United Kingdom Influenza Treatment Market Size, Share & Trends Analysis Report By Product (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy) and Forecasts, 2026-2034

United Kingdom Influenza Treatment Market Growth Factor

Rising Incidence of Seasonal Influenza Outbreaks

The seasonal influenza outbreak is a significant driver of the market in the United Kingdom. The UK typically experiences annual flu outbreaks, peak flu seasons between December and February. According to the National Health Service (NHS), influenza-related hospitalizations have been on the rise in recent years, particularly among vulnerable populations such as older people and those with chronic conditions.

• For instance, in 2024, NHS reported an increase in flu-related hospital admissions, primarily affecting the elderly and children.

Moreover, as the virus mutates and new strains emerge, the demand for antiviral treatments also increases. This trend will continue as seasonal flu outbreaks become more frequent and severe. The aging population in the UK, with over 18% of the population over the age of 65, further exacerbates the demand for effective antiviral treatments. Consequently, the increase in cases has bolstered the growth of the antiviral drug market in the UK.

Restraining Factor

Challenges in Vaccine and Antiviral Drug Access

Despite the growing demand for antiviral treatments, the market faces challenges related to access to vaccines and antiviral medications, especially in rural and underserved areas. The UK’s National Health Service (NHS) provides free flu vaccinations for high-risk groups; however, there are still regions where vaccination rates are below the target. Additionally, although antiviral drugs are widely available, some patients face delays in accessing treatment due to logistical issues within the healthcare system.

Additionally, the accessibility issue can be especially critical for high-risk patients, such as the elderly and those with underlying health conditions, who are more susceptible to severe influenza complications. These challenges may limit the reach of treatment initiatives and hinder market growth, especially in areas where healthcare resources are stretched thin.

Market Opportunity

Advancements in Antiviral Drug Development

One of the most significant opportunities for the United Kingdom's influenza treatment market lies in the continuous development of more effective and safer antiviral drugs. The rise of locally acting antiviral agents drugs that target the virus at its site of infection has spurred new growth opportunities. Locally acting antiviral agents, such as baloxavir marboxil, are gaining approval and adoption in the UK market due to their ability to reduce the duration of illness and improve patient outcomes with fewer side effects.

Furthermore, the UK’s strong pharmaceutical sector, home to major companies such as GlaxoSmithKline and AstraZeneca, continues to drive innovation in the treatment space. The country’s investment in biomedical research and drug development ensures that new antiviral medications, including those targeting drug-resistant flu strains, will contribute to the market’s expansion. Additionally, the integration of Artificial Intelligence (AI) in drug discovery is expected to accelerate the development of more effective treatments, creating substantial growth opportunities for the UK influenza treatment market.

Drug Types Insights

Locally Acting Antiviral Agents dominate the drug type segment and are expected to grow at a CAGR of 3.3% over the forecast period. Locally acting antivirals, which target the influenza virus directly at the site of infection, offer significant advantages over traditional antiviral treatments, including reduced side effects and faster recovery. This category includes drugs such as baloxavir marboxil, which is gaining popularity due to its effectiveness and reduced pill burden. With increasing adoption in hospitals and clinics, locally acting antivirals are expected to dominate the market in the coming years. The preference for targeted treatments and the growing demand for flu-specific medications support the continued expansion of this segment.

End User Insights

Hospitals and clinics remain the largest end-users of influenza treatments in the United Kingdom, with a projected growth rate of 3.6% during the forecast period. The country’s healthcare system is well-equipped to manage influenza cases, with hospitals as the primary sites for flu treatments, especially during peak flu seasons. NHS hospitals are critical in managing flu-related hospitalizations, particularly treating high-risk groups such as the elderly. The increasing flu-related hospital admissions during seasonal outbreaks will continue to drive demand for antiviral treatments in these healthcare settings, ensuring steady growth for this segment.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Countrywise Insights

The market is characterized by the country’s robust healthcare system, increasing influenza outbreaks, and a focus on prevention and treatment.

• London plays a central role in the influenza treatment market as the UK's capital city. With a large population and numerous healthcare facilities, including prestigious institutions like St. Thomas' Hospital and King's College Hospital, the city is at the forefront of treatment. London’s dense population and frequent outbreaks during flu season contribute significantly to the demand for antiviral medications. Additionally, London’s access to cutting-edge medical research and pharmaceutical companies further strengthens its position as a key market for influenza treatments.
• Manchester, one of the largest cities in the UK, also sees a high demand for influenza treatments, particularly in its extensive hospital network, including the Manchester Royal Infirmary. The city's healthcare infrastructure ensures that the population receives timely treatment during flu season. Manchester’s commitment to public health initiatives, such as flu vaccination programs, supports the growing demand for antiviral drugs. The city's aging population further amplifies the need for effective flu treatments.
• Birmingham, the second-largest city in the UK, has a significant presence of healthcare facilities like the Queen Elizabeth Hospital, which plays a crucial role in influenza treatment. Birmingham’s diverse population and many elderly residents make it a key market for antiviral drugs. The city's hospitals and clinics are central to providing treatment during outbreaks, and the ongoing investments in healthcare infrastructure ensure that antiviral medications are readily accessible.
• Liverpool, with its extensive healthcare network and large student population, also experiences high seasonal flu rates. Hospitals such as the Royal Liverpool University Hospital are integral to providing treatments. The city’s demographic, with a mix of young adults and elderly citizens, creates varied demands for antiviral therapies. The increase in flu-related hospitalizations during winter ensures that Liverpool remains a critical region for the influenza treatment market.
• Edinburgh, the capital city of Scotland, experiences seasonal flu outbreaks, particularly among its elderly population. The city’s healthcare system, led by institutions such as the Western General Hospital, is essential for influenza care. Edinburgh’s high vaccination rates and health awareness initiatives also contribute to the demand for effective antiviral treatments. The city’s role as a significant healthcare and research hub further supports the market's growth.

List of Key and Emerging Players in United Kingdom Influenza Treatment Market

• Roche Holding AG
• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi S.A.
• Seqirus (a subsidiary of CSL Limited)
• Johnson & Johnson
• Pfizer Inc.
• Novartis International AG
• Daiichi Sankyo Company, Limited
• Mylan N.V.